Life Science Compliance Update

January 15, 2018

Maine Updates Their Gift to Physicians Law Online


Maine has posted a revised version of their gifts to physicians law which bans cash payments from pharmaceutical manufacturers, wholesalers agents for research, consulting, promotional speaking related payments but exempts educational materials, modest meals, prescription drug samples, honorarium at educational events and education-related funding to institutions.

We have previously written about the Maine Legislature passing a new law to prohibit gifts from industry to health care practitioners.

On November 1, 2017, the law went into effect and can now be found online for reference.

For a refresher, the law amends the Maine Pharmacy Act to prohibit a person engaged in the manufacture of prescription drugs or a person who buys prescription drugs for resale and distribution to persons other than consumers from giving a gift to an individual who is licensed, registered or otherwise authorized in the appropriate jurisdiction to prescribe and administer drugs in the course of that individual's professional practice.

However, some significant changes seem to be made to the version listed on the Maine legislative site. Whereas previously there was a list of seven items specifically excluded from the bill, the final legislation does not include that same list.  Instead, the law prohibits manufacturers or wholesalers from offering or giving cash gifts in any amount of a gift for which reciprocity is expected or implied to a health care practitioner.

Further, the list of exceptions has shrunk to a handful. The exceptions include:

  • Giving noncash items of minimal value that will directly benefit the practitioner’s patients including:
    • Prescription drug samples for distribution to patients,
    • Educational materials
  • Modest meals and refreshments that are provided in connection with a meeting or presentation about the benefits, risks and appropriate uses of prescription drugs or medical devices, as long as the meeting or presentation occurs in a venue and manner conducive to informational communications;
  • Giving funding to an academic institution, residency program, or and fellowship program to support the participation of medical, nursing, physician assistant, veterinarian and pharmacy students, residents and fellows in professional meetings, including educational meetings, as long as the program identifies such funding recipients based on independent institutional criteria and the funds are distributed to recipients without specific attribution to sponsors;
  • Giving reasonable honoraria to a practitioner and making payment of reasonable expenses of a practitioner at a professional or educational conference or meeting.

We also recently reviewed the Maine Office of Professional and Occupational Regulation (OPOR) Regulatory Agenda to get a status update. The agenda notes that the Maine Board of Pharmacy expects to get involved in rule-making activity on the topic in 2017-2018.

From the Agenda,

Rulemaking activity is currently under consideration for purposes of implementing 2017 Public Law Chapter 249 to establish procedures and standards to Board-certify a pharmacist to prescribe naloxone hydrochloride and procedures and standards on the dispense naloxone hydrochloride (see chapter 40 below). The Board may consider rulemaking for purposes of implementing 2017 Public Law Chapter 267 on appropriateness of certain gifts extended by manufacturers or wholesale distributors to health care practitioners for which is major substantive rulemaking. In addition, the Board is expected to review rules overall streamlining, to ensure compliance with current laws, and to update rules by addressing outdated references, providing clarification of certain rules as necessary, and setting licensing requirements and operating standards for newly identified types of retail pharmacies.

While most of us like to be prepared and work hard to ensure full compliance with all laws, with no guidance or rule adoption of these laws, companies cannot be found in violation of the laws. Therefore, you still have time to comply while preparing your company for the laws once they take effect.

This change of language has no exemption for research or consulting. We encourage you to review the rules in their entirety to determine what changes if any, your company needs to take.

January 08, 2018

New Jersey Finalizes “Gift” Ban of Physicians Working with the Pharmaceutical Industry


In an unusual administrative move – without passing any new laws – on December 22, 2017, the Attorney General of New Jersey finalized new rules governing physician interactions with pharmaceutical companies.  The rule is titled:   LIMITATIONS ON AND OBLIGATIONS ASSOCIATED WITH PRESCRIBER ACCEPTANCE OF COMPENSATION FROM PHARMACEUTICAL MANUFACTURERS.

Starting January 15, 2018, all contracts and payments entered into by physicians directly with the pharmaceutical industry will be subject to a $10,000 total yearly cap for New Jersey physicians with all pharmaceutical companies. This includes payments from industry for consulting and speaking but exempts research and education related payments. In addition, physicians will be subject to a $15 dollar meal cap, for meals related to all activities.

The rule is scheduled to be published on January 16, 2018, in the NJ state registry.   The writers at Policy and Medicine have created a "clean" version of the final rule without the edit marks and comments for companies and physicians to utilize in their compliance programs. 

It is worth noting that this rule is the first of its kind for any state to adopt a rule that compliance with the rule is tied to physician licensure and applies not to the pharmaceutical manufacturers but to physicians.

We have previously written about the proposed “gift ban” in New Jersey wherein New Jersey Governor Chris Christie proposed a regulation to cap the amount physicians are able to earn annually from drug companies at $10,000.

The original legislation attempted to:

  • Delineate prohibited items to include cash, gift cards, entertainment and recreational items; items for prescriber’s personal use; payments supporting non-faculty attendance at promotional activities; and continuing education events;
  • Establish some exemptions from these prohibitions where the purpose is for the benefit of patients or prescriber education, such as educational materials;
  • Set standards for agreements by which prescribers are paid for “bona fide services,” i.e., speaking at promotional activities and continuing education events, participation in advisory bodies and under consulting arrangements;
  • Require the terms of those agreements to be in writing, with dollar amounts and an articulation of the prescriber’s expertise;
  • Allow for and defining the value (not to exceed $15 for each provider) and “modest” meals that can be provided in different settings 
  • Cap the compensations for bona fide services (with the exception of speaking at continuing education events) from all manufacturers at $10,000 every calendar year.

Following its publication in the New Jersey Register on October 2, 2017, a hearing was held on October 19, 2017, where Attorney General Christopher S. Porrino noted that it was his intent, and the intent of other officials present at the meeting, to move forward with the proposed rules. As we previously noted, the hearing was short with only thirteen speakers present, most of whom warned about possible unintended consequences of the legislation.

The Final Rule


Bona fide services: those services provided by a prescriber pursuant to an arrangement formalized in a written agreement including, but not limited to, presentations as speakers at promotional activities and education events, participation on advisory boards, and consulting arrangements. Does not include services provided by a prescriber in connection with research activities. All agreements must be in writing, shall specify the services to be provided and the dollar value of the consideration to be received by the prescriber and identify the following:

  1. The legitimate need for services in advance;
  2. The connection between the competence, knowledge, and expertise of the prescriber and the purpose of the arrangement;
  3. How participation of the prescriber is reasonably related to achieving the identified purpose;
  4. The manner by which the prescriber will maintain records concerning the arrangement and the services provided by the prescriber; and
  5. An attestation that the prescriber's decision to render the services is not unduly influenced by a pharmaceutical manufacturer's agent.

Education Event: an education event, third-party scientific or educational conference, professional meeting or workshop, seminar, U.S. Food and Drug Administration required education and training, or any other gathering, held in a venue that is appropriate and conducive to informational communication and training about healthcare information, where:

  1. The gathering is primarily dedicated, in both time and effort, to promoting objective scientific and educational activities and discourse (one or more educational presentation(s) should be the highlight of the gathering); and
    2. The main purpose for bringing attendees together is to further their knowledge on the topic(s) being presented.

Modest meals: food and/or refreshment, where its fair market value does not exceed $15.00 for each prescriber.

Non-faculty: a prescriber who does not serve as a speaker or provide actual and substantive services as a faculty organizer or academic program consultant for an education event or for a promotional activity.

Pharmaceutical manufacturer: any entity that

  1. Is engaged in the production, preparation, propagation, compounding, conversion, or processing of prescription drugs or biologics, by extraction from substances of natural origin, or independently by means of chemical synthesis; or
    2. Is directly engaged in the packaging, repackaging, labeling, relabeling, or distribution of prescription drugs or prescription biologics, provided, however, that "pharmaceutical manufacturer" or "manufacturer" shall not include a healthcare facility licensed by the Department of Health, or a pharmacy holding a permit issued by the Board of Pharmacy.

Pharmaceutical manufacturer's agent: a person who, while employed by, or under contract with, a pharmaceutical manufacturer, engages in detailing, promotional activities, or other marketing of prescription drugs or biologics to any prescriber authorized to prescribe, dispense, or purchase prescription drugs, biologics, healthcare facility, or pharmacist, but shall not include a prescriber or pharmacist when acting within the ordinary scope of the practice for which he or she is licensed.
Prescriber: a physician, podiatrist, physician assistant, advanced practice nurse, dentist, or optometrist. It does not include a licensee who is an employee of a pharmaceutical manufacturer who does not provide patient care.
Promotional activity: any unaccredited activity, meeting, or program organized or sponsored by a pharmaceutical manufacturer, or the manufacturer's agent, that is directed at prescribers to promote the prescription, recommendation, supply, administration, use, or consumption of the manufacturer's products through any media or medium. Does not include an education event or services provided in connection with research activities.

Research: any study assessing the safety or efficacy of prescribed products administered alone or in combination with other prescribed products or other therapies, or assessing the relative safety or efficacy of prescribed products in comparison with other prescribed products or other therapies, or any systemic investigation, including scientific advising on the development, testing and evaluation, that is designed to develop or contribute to general knowledge, or reasonably can be considered to be of significant interest or value to scientists or prescribers working in a particular field.

Prohibited Gifts and Payments

A prescriber shall not accept any financial benefit from any pharmaceutical manufacturer or manufacturer’s agent. This includes any item of value that does not advance disease or treatment education, including:

  1. Pens, note pads, clipboards, mugs, or other items with a company or product logo;
  2. Items intended for the personal benefit of the prescriber or staff, such as floral arrangements, sporting equipment, artwork, or items that may have utility in both the professional and non-professional setting, such as electronic devices;
  3. Any payment in cash or cash equivalent, such as a gift certificate;
  4. Any payment or direct subsidy to a non-faculty prescriber to support attendance at, or as remuneration for time spent attending, or for the costs of travel, lodging, or other personal expenses associated with attending any education event or a promotional activity. 

These rules also apply to any immediate family member of a prescriber, unless an immediate family member is employed by a pharmaceutical manufacturer and receives the prohibitions listed as part of the usual and customary employment relationship, compensation, financial benefit, or other item of value.

Permitted Gifts and Payments

A prescriber may accept the following from a pharmaceutical manufacturer or manufacturer’s agent:

  1. Items designed primarily for educational purposes for the patients or the prescriber that have minimal or no value to the prescriber outside of his or her professional responsibilities. This includes anatomical models for use in an examination room or other information and materials in any form directly related to patient care or prescriber education. Items that may have an independent value to the prescriber outside of his or her professional responsibilities, such as electronic devices, may only be accepted if they are used by patients and remain in a common area of the prescriber's office.
  2. A pharmaceutical manufacturer subsidized registration fee at an education event, if that fee is available to all event participants.
  3. Modest meals provided through the event organizer at an education event, provided the meals facilitate the educational program to maximize prescriber learning.
  4. Modest meals provided by a manufacturer to non-faculty prescribers through promotional activities.
  5. Compensation, based on FMV, for providing bona fide services as a speaker or faculty organizer or academic program consultant for an education event. A prescriber serving in this capacity may also accept reasonable payment and remuneration for travel, lodging, and other personal expenses associated with such services. A prescriber may be granted continuing education credit for participation in such activities, if the continuing education requirements of the prescriber's professional licensing board are satisfied.
  6. Compensation, based on FMV, for providing bona fide services as a speaker or faculty organizer or academic program consultant for a promotional activity, consistent with such caps as set forth at N.J.A.C. 13:45J-1.6. A prescriber serving in this capacity also may accept reasonable payment or remuneration for travel, lodging, and other personal expenses associated with such services. A prescriber may not claim continuing education credit for participation in such activities.
  7. Compensation, based on FMV, for participation on advisory bodies or under consulting arrangements, consistent with such cap as set forth at N.J.A.C. 13:45J-1.6. A prescriber serving in this capacity also may accept reasonable payment or remuneration for travel, lodging, and other personal expenses associated with such services.
  1. Reasonable payment or remuneration for travel, lodging, and other personal expenses in connection with research activities.
  1. Reasonable payment or remuneration to prospective applicants for travel, lodging, and other personal expenses associated with employment recruitment.
  1. Royalties and licensing fees paid in return for contractual rights to use or purchase a patented or otherwise legally recognized discovery for which the prescriber holds an ownership right.

Disclosure Requirements

A prescriber serving as a speaker at an education event or for a promotional activity shall directly disclose to attendees either orally or in writing at the beginning of the presentation that the prescriber has accepted payment for bona fide services from the sponsoring pharmaceutical manufacturer within the preceding five years.

Comments and Responses

Any comments were due on December 1, 2017, and on December 22, 2017, the New Jersey government quietly finalized the regulation, albeit with some changes from the proposed rule.

Some of the comments expressed concern that while the rules were proposed to curtail opioid abuse, they were not in line to accomplish that goal and would instead of a broader impact beyond just opioids. The Attorney General’s response acknowledged the truth behind those comments, “the intent of the rules is to apply to all prescription medications so as to ensure that patient care is guided by the unbiased, best judgment of the treating prescriber.”

Additional commenters expressed concern about the unintended consequences of the rules on clinical trials and research because “bona fide services” is too broad of a definition and would encompass payments in connection with vital clinical research, potentially restricting the ability of providers and manufacturers to conduct life-saving research in New Jersey and negatively impacting the advancement of medicine and commercial drug development.

 According to the Adoption Notice, commenters believe that it is unrealistic to expect a physician to conduct a clinical trial for $10,000, and to impose such a limit would guarantee that clinical trials are driven out of New Jersey, with severe impact to the professionals and institutions that have contributed to so many cures. Some comments even went so far as to propose new language for the regulation that would clarify definitions and not put New Jersey in such a disadvantageous position. In response to these comments, the AG amended the bona fide services cap to exclude activities that further “research.”

Several commenters noted that the $15 dollar meal limit was unworkable, as even breakfast any 3 star hotels in New Jersey are over $40 after tax and services are added.  The AG did drop the 4 meals per year per company limit proposed in the original version of the rule. 

Several of the comments opined that the $10,000 figure was too high and should be reduced to $5,000, but the AG found the figure to be appropriate and did not lower it.

In response to several comments about education, the AG amended the term “continuing education event” to “education event,” and amended the definition to include a workshop or seminar and to remove the requirement that “responsibility for and control over the selection of content, faculty, educational methods, materials, and venue belongs to the event’s organizers in accordance with the standards of a nationally recognized accrediting entities.” As such, payments to prescribers speaking at both accredited and non-accredited education programs that meet the definition of an education event and, are for fair market value and are set forth in a written agreement will not be included in the $10,000 cap.


Companies have until January 15, 2018, to enter into any contracts with New Jersey Health Care providers that may exceed the $10,000 total cap for promotional speaking and consulting payments.

Unfortunately, these types of rules often work against their stated purpose which is to fight the “Opioid Crisis” our review of the open payments database showed a modest use of payments to physicians by opioid companies in New Jersey. Rather than consulting with companies to determine the optimal use for their products, NJ physicians will have to pay close attention to their payments or find outside work in the legal industry suing or defending those companies.

One part of the rule which will get the most press attention (pens, note pads, clipboards, mugs, or other items with a company or product logo) deals with a practice in which the pharmaceutical industry has not participate in over 10 years. The level of miss information from policymakers can sometimes be baffling.

Pharmaceutical Research and Manufacturers of America (PhRMA) also has a code of ethics regarding such gifts. However, as we have seen time and time again, those pre-existing codes and rules which are closely followed by industry, do little to stop the behemoth of the regulatory state from setting in.

Key Documents


 Final New Jersey Physician Regulation - rule only 12-22-17

Final Rule incorporating changes from proposed rule - unofficial version - eliminating the need to review the proposed rule in reading the rule.

Proposed Rule 10-2-17




October 31, 2017

Will Your Whistle Be Heard at Home?

Gavel for Web_1501701152664_10176751_ver1.0

The distinct split between the Second and Fifth Circuit Courts’ interpretation as to when whistleblower protections are allowed has now summoned the attention of the U.S. Supreme Court. Despite clarifications issued in 2015 by the SEC to shed more clarity on Dodd Frank’s anti-retaliation protection to whistleblowers who reported alleged misconduct either internally to company officials or externally to government regulatory bodies, the U.S. Supreme Court will take the case of Digital Realty Trust v. Somer in the Fall of 2017, and finally render a final verdict for when whistleblower protection becomes enforceable. During the interim, it becomes vital for Compliance Officers to have appropriate policies and procedures in place to guide employees in reporting potential misconduct and/or fraud, and to establish a tone of non-retaliation for such reporting, in order to safeguard the best interests of the public and shareholders of the company.

As a result of the financial crisis during 2007-2010, the Dodd- Frank Wall Street Reform and Consumer Protection Act (“Dodd-Frank”) was signed into federal law in July 2010 by President Obama to prevent the economic “meltdown” from happening again.

Ostensibly, the legislation was primarily designed to increase overall regulation of the financial industry. However, and perhaps more importantly for compliance professionals, Dodd-Frank also contained a number of enhanced provisions designed to encourage and protect whistleblowers in and outside of the financial industry. These new provisions expanded upon earlier provisions contained in the Sarbanes- Oxley Act of 2002 (“SOX”).

To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In


Preview | Powered by FeedBlitz


January 2018
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31